Patents by Inventor Andreas Schoop

Andreas Schoop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10919902
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: February 16, 2021
    Assignee: Alkermes, Inc.
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • Publication number: 20200247814
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: December 26, 2019
    Publication date: August 6, 2020
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • Patent number: 10421756
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: September 24, 2019
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop
  • Publication number: 20180194760
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: July 5, 2016
    Publication date: July 12, 2018
    Inventors: Martin R. JEFSON, John A. LOWE, III, Fabian DEY, Andreas BERGMANN, Andreas SCHOOP
  • Publication number: 20180194769
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: July 5, 2016
    Publication date: July 12, 2018
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • Patent number: 9981920
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 29, 2018
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Martin R. Jefson, Fabian Dey, Konstanze Konig von Paumbshausen, Adrian Schomburg, Andreas Schoop, Russell John Thomas
  • Publication number: 20170204070
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: June 25, 2015
    Publication date: July 20, 2017
    Inventors: Martin R. Jefson, Fabian Dey, Konstanze Konig von Paumbshausen, Adrian Schomburg, Andreas Schoop, Russell John Thomas
  • Patent number: 9243000
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: January 26, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lars Van Der Veen, Darryl McConnell, Siegfried Schneider, Matthias Grauert, Andreas Schoop, Tobias Wunberg
  • Patent number: 8623887
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2, R4, Rg, X, m, n and p are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: January 7, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephan Karl Zahn, Bojan Bister, Guido Boehmelt, Ulrich Guertler, Andreas Mantoulidis, Ulrich Reiser, Andreas Schoop, Flavio Solca, Ulrike Tontsch-Grunt, Matthias Treu
  • Publication number: 20130281429
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: March 26, 2013
    Publication date: October 24, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl ZAHN, Guido BOEHMELT, Andreas MANTOULIDIS, Ulrich REISER, Matthias TREU, Ulrich GUERTLER, Andreas SCHOOP, Flavio SOLCA, Ulrike TONTSCH-GRUNT, Ralph BRUECKNER, Charlotte REITHER, Lars HERFURTH, Oliver KRAEMER, Heinz STADTMUELLER, Harald ENGELHARDT
  • Patent number: 8420630
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 16, 2013
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Patent number: 8232283
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are inhibitors or kinases such as Raf, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: July 31, 2012
    Assignee: Forma Therapeutics, Inc.
    Inventors: Andreas Schoop, Alexander Backes, Joachim Vogt, Lars Neumann, Jan Eickhoff, Stefan Hannus, Kerrin Hansen, Peter Amon, Igor Ivanov, Matthias Borgmann, Chase Smith, Arthur F. Kluge, Krishan Murthi, Rebecca Casaubon
  • Patent number: 8207349
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • Publication number: 20120108618
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: April 22, 2010
    Publication date: May 3, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Lars Van Der Veen, Darryl Mcconnell, Siegfried Schneider, Matthias Grauert, Andreas Schoop, Tobias Wunberg
  • Publication number: 20110257207
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are inhibitors or kinases such as Raf, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: May 12, 2011
    Publication date: October 20, 2011
    Applicants: Agennix USA Inc, Agennix AG
    Inventors: Alexander BACKES, Joachim VOGT, Peter AMON, Igor IVANOV, Stefan HANNUS, Matthias BORGMANN, Kerrin HANSEN, Rebecca CASAUBON, Chase SMITH, Krishna MURTHI, Arthur KLUGE, Andreas SCHOOP, Lars NEUMANN, Jan EICKHOFF
  • Publication number: 20110251174
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 14, 2011
    Publication date: October 13, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl ZAHN, Guido BOEHMELT, Andreas MANTOULIDIS, Ulrich REISER, Matthias TREU, Ulrich GUERTLER, Andreas SCHOOP, Flavio SOLCA, Ulrike TONTSCH-GRUNT, Ralph BRUECKNER, Charlotte REITHER, Lars HERFURTH, Oliver KRAEMER, Heinz STADTMUELLER, Harald ENGELHARDT
  • Publication number: 20110086842
    Abstract: The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: December 20, 2010
    Publication date: April 14, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Heinz STADTMUELLER, Harald ENGELHARDT, Martin STEEGMAIER, Anke BAUM, Ulrich GUERTLER, Andreas SCHOOP, Jens Juergen QUANT, Flavio SOLCA, Rudolf HAUPTMANN, Ulrich REISER, Stephan Karl ZAHN, Lars HERFURTH
  • Publication number: 20100152167
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Application
    Filed: February 24, 2010
    Publication date: June 17, 2010
    Applicants: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Georg DAHMANN, Frank HIMMELSBACH, Bernd KRIST, Martin LENTER, Alexander PAUTSCH, Gisela SCHNAPP, Martin STEEGMAIER, Helmut WITTNEBEN, Anthony S. PROKOPOWICZ, Walter SPEVAK, Andreas SCHOOP, Steffen STEURER
  • Publication number: 20100144706
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4, X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: December 20, 2007
    Publication date: June 10, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl Zahn, Guido Boehmelt, Ulrich Guertler, Andreas Mantoulidis, Andreas Schoop, Flavio Solca, Ulrike Tontsch-Grunt, Matthias Treu
  • Publication number: 20100113414
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bodo BETZEMEIER, Trixi BRANDL, Steffen BREITFELDER, Ralph BRUECKNER, Thomas GERSTBERGER, Michael GMACHL, Matthias GRAUERT, Frank HILBERG, Christoph HOENKE, Matthias HOFFMANN, Maria IMPAGNATIELLO, Dirk KESSLER, Christian KLEIN, Bernd KRIST, Udo MAIER, Darryl McCONNELL, Charlotte REITHER, Stefan SCHEUERER, Andreas SCHOOP, Norbert SCHWEIFER, Oliver SIMON, Martin STEEGMAIER, Steffen STEURER, Irene WAIZENEGGER, Ulrike WEYER-CZERNILOFSKY, Andreas ZOEPHEL